These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21232670)

  • 21. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world Data on the Efficacy of Vernakalant for Pharmacological Cardioversion in Patients With Recent-onset Atrial Fibrillation.
    Cosin-Sales J; Loscos A; Peiró A; Sorando MR; Buendía F; Ruescas L
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):619-20. PubMed ID: 27131972
    [No Abstract]   [Full Text] [Related]  

  • 23. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN; Eschenhagen T
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
    Akel T; Lafferty J
    Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12508. PubMed ID: 29105209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?
    Camm AJ
    Curr Cardiol Rev; 2014 Nov; 10(4):309-14. PubMed ID: 24821654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atrial flutter with 1 : 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation.
    Franzini C; Müller-Burri SA; Shah DC
    Europace; 2014 Jan; 16(1):3. PubMed ID: 24344323
    [No Abstract]   [Full Text] [Related]  

  • 27. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA; Lau YC; Lip GY
    Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent-onset atrial fibrillation in patients with left ventricular dysfunction: amiodarone or vernakalant?
    Conde D; Costabel JP; Alves de Lima A
    Can J Cardiol; 2013 Oct; 29(10):1330.e11-1330.e12. PubMed ID: 23639270
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
    Tian D; Frishman WH
    Cardiol Rev; 2011; 19(1):41-4. PubMed ID: 21135602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of conversion of recent-onset atrial fibrillation treated with vernakalant.
    Costabel JP; Lambardi F; Aragón M; Campos R; Urdapilleta M; Ariznavarreta P; Vergara JM; Conde D
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):196-200. PubMed ID: 25469647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Usefulness of Vernakalant in Maintaining Sinus Rhythm During Ablation Procedures.
    Juliá J; López-Gil M; Villagraz L; Lozano Á; Fontenla A; Arribas F
    Rev Esp Cardiol (Engl Ed); 2016 Jul; 69(7):708-9. PubMed ID: 27235290
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
    Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
    J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring.
    Manolis AS; Bethanis S; Metaxa S; Polytarchou K; Sakellaris N; Pyrros I
    Hellenic J Cardiol; 2019; 60(1):54-56. PubMed ID: 29454598
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of vernakalant and ranolazine in atrial fibrillation.
    Frommeyer G; Sterneberg M; Dechering DG; Kochhäuser S; Bögeholz N; Fehr M; Eckardt L
    J Cardiovasc Med (Hagerstown); 2017 Sep; 18(9):663-668. PubMed ID: 28692548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient.
    Friederich P; Pfizenmayer H
    Br J Anaesth; 2011 Oct; 107(4):644-5. PubMed ID: 21903653
    [No Abstract]   [Full Text] [Related]  

  • 40. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
    Ehrlich JR; Nattel S
    Curr Opin Cardiol; 2009 Jan; 24(1):50-5. PubMed ID: 19077816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.